Century Therapeutics updates pipeline; CNTY-101 shows durable responses, no allo-rejection in Ph1

Century Therapeutics, Inc.

CNTY-101 (CD19 iNK) in Ph1 ELiPSE-1 shows favorable safety, 2 CRs including 6-month durable CR, no allo-rejection.
Plan to initiate Ph1 CALiPSO-1 trial in SLE in H1 2024; initial data expected by YE 2024.
Cash, cash equivalents, and investments of $261.8M at end of Q4 2023; runway into 2026.
Platform includes Allo-Evasion edits enabling repeat dosing without lymphodepletion; advancing iNK and γδ iT cell programs.
Additional ELiPSE-1 data expected mid-2024; pursuing additional autoimmune health authority filings in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.